Cancer Screening


What is Cervical cancer?

Cervical cancer is the 2nd most common female cancer in women aged 15 to 65 years.

When exposed to HPV (Human Papilloma virus) a woman’s immune system typically prevents the virus from doing harm, however the virus survives for years, that causes some cells on the surface to become cancer cells after sometime of exposure.

Symptoms of Cervical cancer

Early stage cervical cancer generally produces no signs or symptoms.

Symptoms of more advanced cervical cancer include – watery discharge with foul odor, vaginal bleeding after intercourse, between periods or after menopause, pelvic pain.

Diagnosis of Cervical Cancer

Leading health organizations – ACOG, ACS, ASCP & ASCCP recommend that PAP (LBC) + HPV together (co- testing) is the preferred approach for cervical cancer screening.

Cancer Screening

Co-Testing Algorithm:

Advantages of Cervical screening by Liquid Based Cytology (LBC)

  • Sample is collected using Rover’s cervex brush, long bristles cover the endocervix and short ones cover the ectocervix.
  • Cell enrichment process separates and removes blood, mucus and other cells reducing the risk of missed diagnosis.
  • Improves fixation – performed on fully automated Machine.

SurePath LBC Sample Collection

  • The kit used for collecting the LBC sample is a BD SurePath vial
  • Collect sample using Rover’s cervex brush
  • Insert the central bristles into endocervical canal deep enough to allow the shorter bristles to fully contact the ectocervix
  • Push gently, rotate the broom in a clock-wise direction 5 times
  • After collecting the sample, use the interior rim of the BD SurePath collection vial to pull off the head of the broom-like device or place your thumb against the back of the brush pad to snap the heads of the brush and spatula.
  • Place the detached head into the large opening in the collection vial

HPV DNA Detection & Genotype

  • Rapid and confirmatory test.
  • Detects 40 HPV types including 14 high risk and other low risk types.
  • HPV 16/18 is the most carcinogenic HPV that accounts for 75-85% of all cervical cancers.

Recommended approach for cervical cancer screening:

  • Co-testing (LBC + HPV) is the preferred approach recommended by leading health organizations
  • Screening Recommendations: